Cargando…

Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins

The binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Janisova, Larisa, Gruzinov, Andrey, Zaborova, Olga V., Velychkivska, Nadiia, Vaněk, Ondřej, Chytil, Petr, Etrych, Tomáš, Janoušková, Olga, Zhang, Xiaohan, Blanchet, Clement, Papadakis, Christine M., Svergun, Dmitri I., Filippov, Sergey K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076460/
https://www.ncbi.nlm.nih.gov/pubmed/32013056
http://dx.doi.org/10.3390/pharmaceutics12020106
_version_ 1783507221897805824
author Janisova, Larisa
Gruzinov, Andrey
Zaborova, Olga V.
Velychkivska, Nadiia
Vaněk, Ondřej
Chytil, Petr
Etrych, Tomáš
Janoušková, Olga
Zhang, Xiaohan
Blanchet, Clement
Papadakis, Christine M.
Svergun, Dmitri I.
Filippov, Sergey K.
author_facet Janisova, Larisa
Gruzinov, Andrey
Zaborova, Olga V.
Velychkivska, Nadiia
Vaněk, Ondřej
Chytil, Petr
Etrych, Tomáš
Janoušková, Olga
Zhang, Xiaohan
Blanchet, Clement
Papadakis, Christine M.
Svergun, Dmitri I.
Filippov, Sergey K.
author_sort Janisova, Larisa
collection PubMed
description The binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric drug delivery system based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (pHPMA) with the most abundant proteins in human blood plasma—namely, human serum albumin (HSA), immunoglobulin G (IgG), fibrinogen (Fbg), and apolipoprotein (Apo) E4 and A1—using a combination of small-angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC), and nuclear magnetic resonance (NMR). Through rigorous investigation, we present evidence of weak interactions between proteins and polymeric nanomedicine. Such interactions do not result in the formation of the protein corona and do not affect the efficiency of the drug delivery.
format Online
Article
Text
id pubmed-7076460
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70764602020-03-20 Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins Janisova, Larisa Gruzinov, Andrey Zaborova, Olga V. Velychkivska, Nadiia Vaněk, Ondřej Chytil, Petr Etrych, Tomáš Janoušková, Olga Zhang, Xiaohan Blanchet, Clement Papadakis, Christine M. Svergun, Dmitri I. Filippov, Sergey K. Pharmaceutics Article The binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric drug delivery system based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (pHPMA) with the most abundant proteins in human blood plasma—namely, human serum albumin (HSA), immunoglobulin G (IgG), fibrinogen (Fbg), and apolipoprotein (Apo) E4 and A1—using a combination of small-angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC), and nuclear magnetic resonance (NMR). Through rigorous investigation, we present evidence of weak interactions between proteins and polymeric nanomedicine. Such interactions do not result in the formation of the protein corona and do not affect the efficiency of the drug delivery. MDPI 2020-01-28 /pmc/articles/PMC7076460/ /pubmed/32013056 http://dx.doi.org/10.3390/pharmaceutics12020106 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Janisova, Larisa
Gruzinov, Andrey
Zaborova, Olga V.
Velychkivska, Nadiia
Vaněk, Ondřej
Chytil, Petr
Etrych, Tomáš
Janoušková, Olga
Zhang, Xiaohan
Blanchet, Clement
Papadakis, Christine M.
Svergun, Dmitri I.
Filippov, Sergey K.
Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
title Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
title_full Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
title_fullStr Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
title_full_unstemmed Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
title_short Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
title_sort molecular mechanisms of the interactions of n-(2-hydroxypropyl)methacrylamide copolymers designed for cancer therapy with blood plasma proteins
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076460/
https://www.ncbi.nlm.nih.gov/pubmed/32013056
http://dx.doi.org/10.3390/pharmaceutics12020106
work_keys_str_mv AT janisovalarisa molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT gruzinovandrey molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT zaborovaolgav molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT velychkivskanadiia molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT vanekondrej molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT chytilpetr molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT etrychtomas molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT janouskovaolga molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT zhangxiaohan molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT blanchetclement molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT papadakischristinem molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT svergundmitrii molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins
AT filippovsergeyk molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins